ABSTRACT
Mesenchymal stem cells (MSCs) are multipotent stromal cells which can differentiate into a variety of cell types including osteoblasts, adipocytes and chondrocytes. They are normally resident in adipose tissue, bone marrow and the umbilical cord, but can also be found in other tissues and are known to be recruited to sites of wound healing as well as growing tumours. The therapeutic potential of MSCs has been explored in a number of phase I/II and III clinical trials, of which several were targeted against graft-versus-host disease and to support engraftment of haematopoietic stem cells (HSCs), but currently only very few in the oncology field. There are now three clinical trials either ongoing or recruiting patients that use MSCs to treat tumour disease. In these, MSCs target gastrointestinal, lung and ovarian cancer, respectively. The first study uses MSCs loaded with a HSV-TK expression construct under the control of the CCL5 promoter, and has recently reported successful completion of Phase I/II. While no adverse side effects were seen during this study, no outcomes with respect to therapeutic benefits have been published. The other clinical trials targeting lung and ovarian cancer will be using MSCs expressing cytokines as therapeutic payload.
Despite these encouraging early steps towards their clinical use, many questions are still unanswered regarding the biology of MSCs in normal and pathophysiological settings. In this review, in addition to summarising the current state of MSC-based therapeutic approaches for cancer, we will describe the remaining questions, obstacles and risks, as well as novel developments such as MSC-derived nanoghosts.
MSCs and their potential use in cancer treatment
MSCs were first isolated and characterised by Friedenstein and his colleagues in the 1960-1970s [1] . They are non-haematopoietic cell precursors, initially found in the bone marrow, but actually present in many other tissues [2] . The International Society of Cellular Therapy (ISCT) uses three criteria to define MSCs [3] : Firstly, MSCs can adhere to plastic under standard culture conditions; secondly, MSCs express cell surface markers including CD105, CD73 and CD90 with no expression of endothelial, haematopoietic, or immunological cell markers such as CD45, CD34, CD14, CD11b, CD79α, CD19 and HLA-DR; thirdly, MSCs have the ability to differentiate into osteoblasts, adipocytes, and chondroblasts when exposed to the appropriate stimuli [4] . MSCs can be readily transduced by a variety of vectors such as Adenovirus, Lentivirus and Adeno-associated virus (AAV) [5] [6] [7] [8] [9] . Owing to their relative immuneprivilege/-evasiveness and general immune-dampening activities, MSCs can be used in an allogenic setting and are therefore well suited as an off-the-shelf cell therapeutic agent [10, 11] .
Even though MSCs have been found in and derived from various tissues, the most frequently used MSCs are from bone marrow (BM-MSCs), adipose tissue (AT-MSCs) and umbilical cord (UC-MSCs) [12] [13] [14] . As for this good availability and the relative straightforward culturing conditions, MSCs gained increasingly clinical attraction over the last ten years including the treatment of cancer. Generally, the use of MSCs as cellular vehicles in the latter context is based on their ability to home to tumours as they are recognised by MSCs as a "wound that never heals" [15] . This tumour tropism is part of the normal repair function in which MSCs are recruited by sites of tissue injury and inflammation. They are capable of extravasating into tumours when introduced into the organism via the blood stream [16] , and although the molecular mechanisms behind the migration of MSCs are still not fully understood, studies have shown that the migration is regulated by various cytokines and their corresponding receptors, i.e. SDF-1/CXCR4, HGF/c-Met, VEGF/VEGFR, PDGF/PDGFR, MCP-1/CCR2, and HMGB1/RAGE [17] .
In the context of such cell therapeutic approaches, MSCs are used as gene delivery vehicles for tumour targeted therapies. In several preclinical cancer models, MSCs have been genetically modified to express cytokines, growth factor antagonists, antiangiogenic factors, prodrug-converting enzymes and proapoptotic proteins ( Fig.   1 and Supplementary Table 1) . Another relatively early-stage approach uses MSCs as carrier for oncolytic viruses [18, 19] . Such modified MSCs have been used in different tumour type models including colon cancer [20, 21] , pancreatic cancer [22] [23] [24] , lung cancer [25] [26] [27] [28] [29] , breast carcinoma [30] [31] [32] , ovarian cancer [33] , prostate cancer [34, 35] , hepatocellular carcinoma [36] [37] [38] [39] , glioma [40] [41] [42] [43] [44] , melanoma [45] , malignant mesothelioma [46] and lymphoma [47] . Although these pre-clinical studies clearly demonstrated therapeutic benefits of MSC-based targeted approaches, very few clinical trials utilising MSCs as delivery vehicles for anti-cancer treatments have been approved [48, 49] . This delay in transition from bench to bedside is at least in parts due to reports that MSCs not only display a potential to undergo malignant transformation, but can also lead to metastasis induction. Both of these issues embody possible barriers for the safe use of MSCs in cancer treatment and will be discussed below.
Potential problems with MSCs in cancer therapies

Do MSCs undergo malignant transformation and form tumours?
In the 2000s it was reported that MSCs could undergo spontaneous, malignant transformation and form tumours in vivo, dramatically increasing the risk of therapeutic use of MSCs [50] [51] [52] . However, these initial reports were subsequently retracted as it turned out that the observed tumour formation was the result of crosscontaminations with cancer cells [53, 54] . In detail, the subsequent analyses showed that the MSC cultures were cross-contaminated with a human sarcoma cell line in one case, and in the second case the presence of two glioma cell lines was detected by DNA fingerprinting and short tandem repeat (STR) analysis [54] . These results underscore the need for stringent cell culture procedures when it comes to the use of primary cell cultures, including MSCs, for therapeutic purposes. Notwithstanding, the acquisition of genetic abnormalities in vitro has been observed by several groups [55] [56] [57] .
However, despite these chromosomal abnormalities no evidence of subsequent malignant transformation was found in these studies [58] . More importantly, there are no reports on MSC-related tumour formation in human patients after MSC administration [59, 60] . It cannot be ruled out though, that there is still a hypothetical and residual risk of developing tumours after treatment with MSCs, which harboured cytogenetic abnormalities at the time of injection or develop them later postadministration. Follow-up studies of patients who received MSCs as part of their treatment will add clarity to their tumorigenic potential. However, out of an abundance of caution standardised purification and expansion protocols should be established, as chromosomal abnormalities are mainly related to culture conditions [61] . As part of these considerations, culture conditions with low proliferation rates and minimal expansion rates are recommended to minimise the risk of acquired chromosomal aberrations [61] .
In conclusion, while the risk from malignant transformation of MSCs has been overstated in the past, it will be essential to put stringent quality-control and standardisation procedures in place for MSCs to fulfil their potential in clinic applications.
MSCs and their pro-metastatic activity
Another issue that arose with MSCs is their potential to promote metastasis development in different cancer models [62] [63] [64] . In this context, MSCs can induce cancer cell dissemination in tumours that normally do not form metastatic lesions, whereas in tumours with a high potential to metastasise, MSCs cannot further increase the dissemination process [62] . The ability of MSCs to promote tumour metastasis was demonstrated in mammary carcinoma mouse models as well as osteosarcoma and colorectal cancer in these reports. While the initial results were obtained from cancer cells co-implanted with MSCs [63] , it was later shown that established tumours could also be induced to form metastatic lesions by systemically administered MSCs, of both human and murine origin [62] .
Currently, several hypotheses how MSCs increase the metastatic potential of tumour cells exist:
(a) MSCs within the tumour stroma secret soluble factors, e.g. CCL5 (also known as RANTES), which increases the metastatic abilities of cancer cells in a paracrine way [63] . In this context, it was also shown that tumour-derived osteopontin (OPN) acts on MSCs and induces the production and release of CCL5 [65] . CCL5 acting via its receptor CCR5 activates AKT/PKB in cancer cells enabling them to survive the different steps of the metastatic process and colonise distal organs [66] . However, other factors and pathways may exist that can also trigger cancer cell dissemination, of which some act in a cell type and context-specific manner and have not yet been identified. (d) MSCs can stimulate epithelial-mesenchymal transition (EMT) of cancer cells [82] and thereby promote the invasiveness of cancer cells they intact with. EMT is a developmental process, in which epithelial cells acquire mesenchymal, fibroblast-like characteristics and show decreased intercellular adhesion and increased motility. As these are features, important for disseminating tumour cells, it was first hypothesised and now has been widely recognised that EMT is also involved in the metastatic process [83, 84] . HGF, EGF, PDGF, TGF-and leptin are factors that can be produced by MSCs [85] [86] [87] , which in turn activate a series of EMT-promoting transcription factors such ZEB1, ZEB2, Slug, Snail, and Twist as well as other EMT-inducing factors such as SERPINE1, MMP-2, and IL-6 [87] [88] [89] [90] . Experimentally, a potential role of MSCinduced EMT has been shown for breast, melanoma, head and neck squamous cell carcinoma, ovarian, endometrial, pancreatic, gastric and colon cancer [88, 89, [91] [92] [93] [94] .
Therefore, the induction of EMT might be the mode of action by which MSCs promote metastasis development, but obviously this function might overlap with some of the other activities ascribed to them and summarised above.
In contrast to these observations there are also reports describing a reduction in tumour growth even in responses to unmodified MSCs, at least in certain cancer models. Such anti-cancer properties were attributed to soluble factors secreted by
MSCs [95] . However, the overall balance lies with cancer-progression-promoting functions of MSCs at this point. Therefore, in the short term MSCs should probably be used only after a careful risk-benefit analysis in humans, in particular in clinical cancer trials. Furthermore, the therapeutic payload should also target metastasising cells and thereby overcome the potential metastasis-promoting activities by stopping disseminating cancer cells in their tracks. In the mid-to-long term, the goal is to develop and use "safe" re-engineered MSCs that lack the expression of one or more pro-metastatic factors (e.g. CCL5, TGF- For this, further investigations in the underlying mechanisms and a deeper understanding of the pro-metastatic effect would be beneficial in the development of such safer MSCs for the treatment of cancer.
However, it will also be crucial to investigate whether the deletion of these genes, while creating "safe" MSCs, also leads to a loss of tumour tropism and therapeutic activity.
The potential impact of MSCs on anti-cancer therapies
The ability of MSCs to create an immunosuppressive environment can be potentially detrimental for their use in cancer therapy. Generally, the effects of anti-cancer therapies are thought to be amplified by immune cells attacking tumour cells marked and/or damaged by the treatment. Thus, MSCs either delivering the therapy or being used in combination with cytotoxic drugs, radiotherapy or biologicals could block or diminish this additional effect and limit the overall therapeutic outcome [96, 97] . In this context it is important to consider the mode of action of the treatments and what type of cell death they trigger. Programmed cell death or apoptosis has regularly been called the silent cell death because it does not lead to an immune response [98] . In such a context, the immune dampening effects of MSCs should be inconsequential and approaches of MSCs delivering bona fide apoptosis inducing agents such as TRAIL should not be affected. However, recent studies have uncovered evidence of paracrine signals originating from dying cells [98] [99] [100] , and in a setting like this, the therapeutic success could indeed be reduced. One way to address this potential problem is to prime MSCs with TLR4 to render them immune competent [101] . This is based on a concept of MSCs being polarised by downstream TLR signalling into two homogenously acting phenotypes classified as MSC1 (immune competent) and MSC2
(immune-suppressive) [102, 103] . Furthermore, the group who characterised the two types of MSCs could show that MSC1-based therapy attenuated tumour growth whereas MSC2-treatment promoted tumour progression [104] . However, further research needs to address whether MSC1-based cell therapies including different therapeutic genes can surpass the efficacy of unprimed MSCs. Fig. 2A ) [48] . The preclinical studies demonstrated growth reduction of hepatocellular and pancreatic carcinoma and also a reduction in metastases [24, 37] . The CCL5 promoter restricts the HSV-TK expression to the tumour microenvironment, so side effects can be minimised. This is based on the fact that MSCs infiltrating tumour tissues start producing the chemokine CCL5 upon contact with cancer cells [63] . Thus, the CCL5 promoter becomes active and will drive therapeutic transgenes that are regulated by it. After cell delivery, the pro-drug ganciclovir will be administered, which is phosphorylated and activated by HSV-TK and consequently gives rise to cancer cell death. In the TREAT-ME1 trial autologous BM-MSCs that are isolated and expanded to passage 1 are used. They are transduced with a gamma-retroviral SIN-vector carrying the CCL5-promoter-HSV-TK expression cassette [48] . The successful completion of Phase I/II was recently announced.
MSCs in preclinical studies and clinical trials
The second clinical trial aims to treat women with recurrent ovarian cancer with IFN- secreting MSCs. For this study, MSCs are isolated from healthy male donors, and genetically engineered MSCs will then be intraperitoneally administered into patients (Fig. 2B) . The use of IFN- is based on results from a study in the early 2000s that showed profound anti-cancer activities in a preclinical melanoma model [45] . IFN- is a cytokine that has been used to treat multiple sclerosis for many years. In cancer treatment it is thought to act through indirect immunomodulatory and antiangiogenic properties or through direct antiproliferative effects on malignant cells [110] .
The third clinical approach using MSCs as gene-therapeutic vehicle aims to deliver the TNF-related apoptosis-inducing ligand (TRAIL). In this trial (TACTICAL), allogeneic MSCs expressing a full-length version of TRAIL (i.e. membrane bound) will be used for the treatment of lung cancer (Fig. 2C ) [47] . TRAIL is a protein that can bind as a ligand to five different receptors, of which two are functional apoptosis-inducing receptors, whereas the other three are so called decoy-receptors [111, 112] . It has been
shown to selectively induce apoptosis in cancer cells and has been clinically tested as recombinant protein and TRAIL receptor-targeting agonistic antibodies [113, 114] .
MSC-delivered TRAIL has been shown to be more potent than these agents and can therefore induce cell death in relatively TRAIL resistant cells [115] . Due to its promising results in initial preclinical studies, MSC-based TRAIL therapies have been continuously improved over the last few years. Firstly, by engineering a soluble form of TRAIL (sTRAIL) enabling it to also act on distant cells, which appears to be important for a wider anti-cancer effect [116] [117] [118] [119] . Secondly, by generating receptor specific variants of sTRAIL, which target specifically one of the two apoptosisinducing TRAIL-receptors, and can therefore, overcome resistance [23, 120, 121] .
Thirdly, MSCs delivering TRAIL have been successfully used in combination therapies [20] .
Other approaches to tackle cancer use MSCs to package and deliver drugs like Palitaxel and Gemcitabine [118, 122] . In contrast to other studies, in which MSCs deliver an enzyme necessary to convert a prodrug into a pharmacologically active drug, primed MSCs do not need to be genetically modified. The loaded MSCs release their cytotoxic payload packed in exosomes at the sites of tumour or metastatic growth [123, 124] . Overall, MSCs can be loaded with a broad spectrum of anti-cancer agents [125] . To do so, multiple packaging methods have been described, ranging from silica nanorattles [126] to liposomes [127] . with recombinant TRAIL demonstrated a marked inhibition of human prostate cancer [144] . Furthermore, in a study to also demonstrate the applicability of MSC-NGs for gene therapy, loading with a plasmid expressing the hemopexin-like domain (PEX) of human matrix metalloprotease-2 gave rise to a significant therapeutic effect both on the primary cancer as well as metastatic lesions [145] [146] [147] . Thus, it might be possible to use MSC-NGs as a tumour cell therapy by proxy in the future. In this context, it is of interest that when MSCs were heat-inactivated (HI-MSC), which means they could no longer respond to inflammatory signals or secrete immunomodulatory factors, they showed the same biodistribution and persistence after infusion in mice with ischemic kidney injury [148] . While in contrast to MSCs, HI-MSC lacked the capability to suppress T-cell proliferation or induce regulatory B-cell formation, they, like MSCs were able to modulate monocyte function in response to lipopolysaccharides. Hence, in specific cases, the functions of MSC, in particular the immunomodulatory effects, do not depend on their set of secreted factors (secretome) or active cross-talk with immune cells, but on recognition of MSC by monocytic cells [148] .
Outlook and remaining questions
The fate of MSCs in vivo
In contrast to other diseases [149] , for the treatment of cancer it appears necessary for MSCs to engraft in the relevant tissues, i.e. primary cancer, dissemination routes (e.g. lymphatic system) and metastatic lesions [45] . However, currently, it is not entirely clear how exogenously administered MSCs behave in the human body but what we know is summarised in Supplementary Table 2 . Multiple studies have demonstrated the presence of MSCs in the lung, immediately after injection [150] [151] [152] [153] [154] . The majority of cells are, however, cleared within the first days of treatment [62, 155] .
Notwithstanding, even after 11 weeks MSCs were still detectable in the lungs, albeit at very low numbers [154] and several other tissues [62] . A human study, examining autopsy material from patients following MSC therapy, only found a low degree of MSC engraftment, and therefore concluded that MSCs exert their function more likely through a ''hit and run'' mechanism rather than through sustained engraftment [59] .
However, all attempts to detect exogenously administered MSCs in recipients' organs suffer from limitations in relation to the respective detection method and can clearly lead to variabilities in the number of detected MSCs [156] [157] [158] . An extra level of variability can be added by using different sources of MSCs and having cultured these cells under different conditions and expansion rates. In this context, it has been shown that extensive expansion, which might be necessary for certain transplantation regimens, negatively impacts on the homing capabilities of MSCs [159] , whereas hypoxic culture conditions increased their migratory potential [160] . Furthermore, the site of MSC delivery can also influence the biodistribution of MSCs and should therefore be considered when designing a study. As it has been shown that intravenously delivered MSCs are entrapped in the lung and cleared to the liver and spleen within a day, this mode of application is suitable for the treatment of tumours like lung cancer, pleural mesothelioma [46] as well as lung and liver metastases [26, 128] . Furthermore, MSCs could be found in the bone marrow and lymph nodes [62] after several weeks, expanding the utility to disseminating disease and those that form metastases in the bone such as prostate cancer. Going forward, it will be important to control the different parameters that determine MSC biodistribution and find optimised administration routes for different cancer treatment applications.
Are Induced MSCs (iMSCs) the future?
Even though MSCs can be cultured relatively easily, their life span is finite and it is a challenge to expand them to the numbers required for clinical trials, let alone routine clinical use in the future. MSCs derived from human induced pluripotent stem cells (iPSC) could offer a solution to these issues and become a virtually inexhaustibly, autologous source of MSCs [161, 162] . These cells, commonly referred to as iMSCs (even though this abbreviation is also used for immune-modulatory MSCs) are generated by culturing iPSCs under specific conditions that regularly involve the use of TGF- inhibitors (e.g. SB-431542) and extracellular matrix material (e.g. Matrigel) [163, 164] . Recently a new method has been described to derive iMSCs directly from primary dermal fibroblasts without the need to go via iPSCs. [165] . iMSCs generated by these methods have been shown to possess high differentiation efficiency into adipocytes, chondrocytes and osteoblasts and to express characteristic MSCs markers.
Functionally, iMSCs display similar strong immunosuppressive characteristics and produce the same range of cytokines as regular MSCs [166] . In the context of MSCbased cancer treatments it has been shown that iMSCs are tumour-tropic but have much less potential to promote tumour progression than bone marrow MSCs. The iMSCs in this study were readily expandable, underwent senescence after prolonged culture and did not form teratomas in vivo [167] . These findings suggest that iPSCderived MSCs are a potentially safer and better option for therapeutic applications in cancer patients. The protocol used in this study is scalable and able to produce the substantial number of cells needed for "off-the-shelf" therapies and bioengineering applications.
Concluding remarks
MSCs provide a powerful treatment modality for tumours owing to a series of beneficial features. However, there are still remaining issues that should be addressed and optimised such as the choice of vector and/or therapeutic gene, the optimal route of administration, the question whether allogenic cells provide a good and safe source or whether they will be replaced by autologous iMSCs in the future. Furthermore, it might be possible to derive so called NGs or exosomes from MSCs to avoid many problems associated with the administration of viable cells, but more work surrounding their use is needed. [3] . LMeC canine melanoma cells established as xenograft model [4] . B16F10 mouse melanoma xenograft model [5] .
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